| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1014906307 |
| P356 | DOI | 10.1007/S40265-015-0455-1 |
| P2888 | exact match | https://scigraph.springernature.com/pub.10.1007/s40265-015-0455-1 |
| P698 | PubMed publication ID | 26330139 |
| P2093 | author name string | David A Johnson | |
| Edward C Oldfield | |||
| Parth J Parekh | |||
| P2860 | cites work | Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients | Q24555072 |
| Duration of dual antiplatelet therapy after drug-eluting stent implantation: a systematic review and meta-analysis of randomized controlled trials | Q26852886 | ||
| Gastrointestinal injury associated with NSAID use: a case study and review of risk factors and preventative strategies | Q27026351 | ||
| Risk of bleeding complications with antiplatelet agents: meta-analysis of 338,191 patients enrolled in 50 randomized controlled trials | Q28166614 | ||
| Compliance as a critical consideration in patients who appear to be resistant to aspirin after healing of myocardial infarction | Q28173982 | ||
| Clopidogrel and ticlopidine: P2Y12 adenosine diphosphate-receptor antagonists for the prevention of atherothrombosis | Q28174320 | ||
| Hospitalisation for upper gastrointestinal bleeding associated with use of oral anticoagulants | Q28188358 | ||
| Cyclooxygenase inhibitors and the antiplatelet effects of aspirin | Q28191912 | ||
| Low-dose aspirin for the prevention of atherothrombosis | Q28193680 | ||
| Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin | Q28195019 | ||
| Gastrointestinal complications of dual antiplatelet therapy | Q28196117 | ||
| Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease | Q28196661 | ||
| Systematic review and meta-analysis of adverse events of low-dose aspirin and clopidogrel in randomized controlled trials | Q28200013 | ||
| Clinical significance of the cytochrome P450 2C19 genetic polymorphism | Q28201086 | ||
| Clopidogrel versus aspirin and esomeprazole to prevent recurrent ulcer bleeding | Q28213463 | ||
| Prevalence of persistent platelet reactivity despite use of aspirin: a systematic review | Q28217967 | ||
| Upper GI risks of NSAIDs and antiplatelet agents: key issues for the cardiologist | Q28219779 | ||
| Effect of antisecretory drugs and nitrates on the risk of ulcer bleeding associated with nonsteroidal anti-inflammatory drugs, antiplatelet agents, and anticoagulants | Q28219972 | ||
| Management of Helicobacter pylori infection--the Maastricht IV/ Florence Consensus Report | Q28264077 | ||
| Platelets modulate gastric ulcer healing: role of endostatin and vascular endothelial growth factor release | Q28365226 | ||
| Endogenous biosynthesis of prostacyclin and thromboxane and platelet function during chronic administration of aspirin in man | Q28366380 | ||
| Ticagrelor versus clopidogrel in patients with acute coronary syndromes | Q29619002 | ||
| A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee | Q29620666 | ||
| Cardiovascular outcomes and mortality in patients using clopidogrel with proton pump inhibitors after percutaneous coronary intervention or acute coronary syndrome | Q33639452 | ||
| Comparative inhibitory activity of rofecoxib, meloxicam, diclofenac, ibuprofen, and naproxen on COX-2 versus COX-1 in healthy volunteers | Q33921099 | ||
| Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study | Q34009506 | ||
| Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study. | Q34020220 | ||
| International consensus recommendations on the management of patients with nonvariceal upper gastrointestinal bleeding | Q34093509 | ||
| Risk of rehospitalization for patients using clopidogrel with a proton pump inhibitor | Q34112291 | ||
| New look at antiplatelet agent-related peptic ulcer: an update of prevention and treatment | Q45019665 | ||
| Risk of upper gastrointestinal bleeding from different drug combinations | Q45333898 | ||
| Pantoprazole significantly interferes with antiplatelet effect of clopidogrel: results of a pilot randomized trial | Q46161142 | ||
| Nonsteroidal anti-inflammatory drug-associated gastropathy: incidence and risk factor models | Q46245351 | ||
| Time dependence of platelet inhibition after a 600-mg loading dose of clopidogrel in a large, unselected cohort of candidates for percutaneous coronary intervention | Q46421411 | ||
| Absorption, metabolization, and antiplatelet effects of 300-, 600-, and 900-mg loading doses of clopidogrel: results of the ISAR-CHOICE (Intracoronary Stenting and Antithrombotic Regimen: Choose Between 3 High Oral Doses for Immediate Clopidogrel Ef | Q46783983 | ||
| Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myoc | Q46868498 | ||
| Prasugrel achieves greater and faster P2Y12receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease | Q46869184 | ||
| Interactions of two major metabolites of prasugrel, a thienopyridine antiplatelet agent, with the cytochromes P450. | Q46895618 | ||
| Prasugrel versus clopidogrel in patients with acute coronary syndromes | Q46915044 | ||
| Esomeprazole with clopidogrel reduces peptic ulcer recurrence, compared with clopidogrel alone, in patients with atherosclerosis. | Q48949658 | ||
| Non-steroidal anti-inflammatory drug-induced small intestinal damage is Toll-like receptor 4 dependent. | Q50467078 | ||
| The disposition of prasugrel, a novel thienopyridine, in humans. | Q50700156 | ||
| The cytochrome 2C19*2 and *3 alleles attenuate response to clopidogrel similarly in East Asian patients undergoing elective percutaneous coronary intervention. | Q53451175 | ||
| Clopidogrel Activities in Patients with Renal Function Impairment | Q59152629 | ||
| ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risks of Antiplatelet Therapy and NSAID Use | Q61667445 | ||
| Risk for Serious Gastrointestinal Complications Related to Use of Nonsteroidal Anti-inflammatory Drugs | Q67903664 | ||
| Dose-related kinetics of aspirin. Presystemic acetylation of platelet cyclooxygenase | Q70503319 | ||
| Cirrhosis does not affect the pharmacokinetics and pharmacodynamics of clopidogrel | Q73667289 | ||
| Risk of hospitalization for upper gastrointestinal tract bleeding associated with ketorolac, other nonsteroidal anti-inflammatory drugs, calcium antagonists, and other antihypertensive drugs | Q74071460 | ||
| Diclofenac acyl glucuronide, a major biliary metabolite, is directly involved in small intestinal injury in rats | Q77620722 | ||
| Pharmacokinetic profile of 14C-labeled clopidogrel | Q78106918 | ||
| A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation | Q79438246 | ||
| Pharmacokinetics of clopidogrel after administration of a high loading dose | Q80371510 | ||
| The platelet inhibitory effects and pharmacokinetics of prasugrel after administration of loading and maintenance doses in healthy subjects | Q83190380 | ||
| A randomized, 2-period, crossover design study to assess the effects of dexlansoprazole, lansoprazole, esomeprazole, and omeprazole on the steady-state pharmacokinetics and pharmacodynamics of clopidogrel in healthy volunteers | Q83780327 | ||
| NSAID-associated lower gastrointestinal bleeding: where do we stand? | Q84731788 | ||
| The use of prophylactic gastroprotective therapy in patients with nonsteroidal anti-inflammatory drug- and aspirin-associated ulcer bleeding: a cross-sectional study | Q86186285 | ||
| Structure and stereochemistry of the active metabolite of clopidogrel | Q34155007 | ||
| 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventi | Q34231154 | ||
| Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic-ulcer disease: a meta-analysis | Q34520598 | ||
| Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities | Q34549376 | ||
| A population-based study of the drug interaction between proton pump inhibitors and clopidogrel | Q34603772 | ||
| Clopidogrel with or without omeprazole in coronary artery disease | Q34660303 | ||
| Systematic reviews of the clinical effectiveness and cost-effectiveness of proton pump inhibitors in acute upper gastrointestinal bleeding | Q34714596 | ||
| Meta-analysis of risk factors for peptic ulcer. Nonsteroidal antiinflammatory drugs, Helicobacter pylori, and smoking | Q34737659 | ||
| Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome | Q34956075 | ||
| Optimal duration of dual antiplatelet therapy after percutaneous coronary intervention with drug eluting stents: meta-analysis of randomised controlled trials | Q35541045 | ||
| Antiplatelet drugs: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines | Q35752619 | ||
| Time-trends in the prescribing of gastroprotective agents to primary care patients initiating low-dose aspirin or non-steroidal anti-inflammatory drugs: a population-based cohort study. | Q36072524 | ||
| Meta-analysis: role of Helicobacter pylori eradication in the prevention of peptic ulcer in NSAID users | Q36158848 | ||
| Cyclo-oxygenase-2 inhibitors or nonselective NSAIDs plus gastroprotective agents: what to prescribe in daily clinical practice? | Q36942298 | ||
| Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects | Q36984424 | ||
| Management of patients with high gastrointestinal risk on antiplatelet therapy | Q37484535 | ||
| Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials | Q37590925 | ||
| Cytochrome P450 2C19*2 polymorphism and cardiovascular recurrences in patients taking clopidogrel: a meta-analysis | Q37721156 | ||
| Antiplatelet drugs: a review of their pharmacology and management in the perioperative period | Q37826579 | ||
| Effects of proton pump inhibitors on platelet function in patients receiving clopidogrel: a systematic review | Q37972025 | ||
| Eradication of Helicobacter pylori infection reduces the incidence of peptic ulcer disease in patients using nonsteroidal anti-inflammatory drugs: a meta-analysis | Q38023606 | ||
| New anticoagulants and antiplatelet agents: a primer for the clinical gastroenterologist | Q38176801 | ||
| Analysis of gastrointestinal prophylaxis in patients receiving dual antiplatelet therapy with aspirin and clopidogrel | Q38181205 | ||
| Should patients prescribed long-term low-dose aspirin receive proton pump inhibitors? A systematic review and meta-analysis | Q38407777 | ||
| Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial | Q38442153 | ||
| Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite | Q39790140 | ||
| Clinical pharmacology of platelet cyclooxygenase inhibition | Q39849855 | ||
| Prasugrel versus clopidogrel for acute coronary syndromes without revascularization | Q40058838 | ||
| NSAIDs, gastrointestinal injury, and cytoprotection | Q40936877 | ||
| A multiple dose study of prasugrel (CS-747), a novel thienopyridine P2Y12 inhibitor, compared with clopidogrel in healthy humans | Q41868121 | ||
| Variability in the pharmacokinetics and pharmacodynamics of low dose aspirin in healthy male volunteers | Q42635960 | ||
| The proton pump inhibitor, omeprazole, but not lansoprazole or pantoprazole, is a metabolism-dependent inhibitor of CYP2C19: implications for coadministration with clopidogrel | Q42728694 | ||
| Mitochondrial damage: a possible mechanism of the "topical" phase of NSAID induced injury to the rat intestine | Q42747553 | ||
| Cardiovascular and Gastrointestinal Outcomes in Clopidogrel Users on Proton Pump Inhibitors: Results of a Large Dutch Cohort Study | Q42926932 | ||
| Cardiovascular risk in clopidogrel-treated patients according to cytochrome P450 2C19*2 loss-of-function allele or proton pump inhibitor coadministration: a systematic meta-analysis | Q42974062 | ||
| Low-dose acetylsalicylic acid use and the risk of upper gastrointestinal bleeding: a meta-analysis of randomized clinical trials and observational studies | Q43063064 | ||
| Pharmacokinetics, pharmacodynamics, tolerability and safety of single ascending doses of ticagrelor, a reversibly binding oral P2Y(12) receptor antagonist, in healthy subjects | Q43187673 | ||
| Nonsteroidal antiinflammatory drugs and risk of gastrointestinal bleeding among patients on hemodialysis. | Q43296805 | ||
| Impact of early versus late clopidogrel discontinuation on stent thrombosis following percutaneous coronary intervention with first- and second-generation drug-eluting stents | Q43417582 | ||
| Upper gastrointestinal bleeding in patients with aspirin and clopidogrel co-therapy | Q44108397 | ||
| P433 | issue | 14 | |
| P304 | page(s) | 1613-1625 | |
| P577 | publication date | 2015-09-02 | |
| P1433 | published in | Drugs | Q3040094 |
| P1476 | title | Current Strategies to Reduce Gastrointestinal Bleeding Risk Associated with Antiplatelet Agents | |
| P478 | volume | 75 |
Search more.